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Abstract  
 
Objectives: Cognitive deficits are a common feature of neuropsychiatric disorders. We 
investigated the relationship between cognitive performance and a deletion allele within 
GluK4 protective against risk for bipolar disorder, in 1642 individuals from the 
TwinsUK study. 
Methods: Cognitive performance was assessed using the National Adult Reading Test, 
four CANTAB tests (Spatial Working Memory, Paired Associates Learning, Pattern 
Recognition Memory, and Reaction Time), and two Principal Component Analysis 
derived factors. Performance in individuals homozygous for the insertion allele was 
compared to deletion carriers and analysis was adjusted for age of diagnosis, medication 
and clinical diagnosis. 
Results: Individuals with the GluK4 protective deletion allele performed significantly 
better in Spatial Working Memory compared to insertion homozygotes when adjusted 
for a clinical diagnosis. GluK4 deletion carriers who had a mental health problem 
(predominately depression) showed better performance in visuo-spatial ability and 
mental processing speed compared to individuals with mental health problems 
homozygous for the insertion.  
Conclusions: These findings of genotype-dependent cognitive enhancement across 
clinical groups support the potential clinical use of the GluK4 deletion allele in 
personalized medicine strategies and provide new insight into the relationship between 
genetic variation and mood disorders. 
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Introduction 
Mood disorders including bipolar disorder, major depression  and anxiety disorders are 
highly heritable, indicating that genetic or heritable epigenetic components contribute 
to risk of developing disease (Cross-Disorder Group of the Psychiatric Genomics et al., 
2013; Genetics of Personality et al., 2015; McCarthy et al., 2014; Song et al., 2015). 
Large genome-wide association studies and whole genome sequencing studies have 
identified common and rare variants which implicate shared neurobiological pathways 
including glutamate neurotransmission involving NMDA, AMPA and KAR receptors 
(Singh et al., 2017; Teng et al., 2017; Witt et al., 2017).  De novo and inherited 
structural variants and point mutations have been identified as risk variants within 
glutamate subunit receptor genes (Frank et al., 2011; Hamdan et al., 2011; Kirov et al., 
2012). These genetic findings support the view that disruption of the glutamatergic 
system contributes to the pathophysiology of mental illnesses. 
Kainate receptors are ionotropic glutamate receptors involved in cellular functions 
necessary for learning and memory, such as synaptic plasticity, long-term potentiation 
and neurotransmission (Bortolotto et al., 1999; Bortolotto et al., 2005; Lerma et al., 
2013; Schmitz et al., 2003; Sihra et al., 2014; Sihra et al., 2013).  They are composed 
of tetrameric combinations of five subunits (GluK1-GluK5; encoded by GRIK1-
GRIK5) and modulated by auxiliary proteins Neto1 and Neto2 (Han et al., 2016; Jane 
et al., 2009; Kristensen et al., 2016; Lerma et al., 2001; Li et al., 2016; Traynelis et al., 
2010). We have previously reported GRIK4/GluK4 as a breakpoint gene disrupted in a 
complex chromosomal rearrangement in a patient diagnosed with schizophrenia co-
morbid with learning disability (Pickard et al., 2008; Pickard et al., 2006). Subsequent 
case control genetic studies led to the identification of a 14 base pair deletion variant 
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(indel) (rs869187535) within the 3’ untranslated region of the gene which was 
negatively associated with bipolar disorder (Knight et al., 2012; Pickard et al., 2006).   
A significant increase in RNA and protein GluK4 expression in the frontal cortex and 
hippocampus correlating with the deletion allele provided some indication that subunit 
availability in specific neuronal populations such as the CA3 mossy fibre region might 
underlie this protective effect (Knight et al., 2012; Pickard et al., 2008). Consistent with 
this model, individuals with the deletion allele were reported to show greater left 
hippocampal activation than insertion homozygotes during a cognitive face processing 
task (Whalley et al., 2009).  
Rodent behavioural studies have provided additional evidence that GluK4 receptor 
subunit function contributes to neuropsychiatric phenotypes and memory function. For 
example, GluK4 knockout mice demonstrate hippocampal-dependent cognitive 
impairments, marked hyperactivity and impaired pre-pulse inhibition which reflect 
aspects of a schizophrenic phenotype (Lowry et al., 2013), whereas mice 
overexpressing Grik4 in the forebrain show anhedonia, depression, anxiety, altered 
social interaction and synaptic transmission, features consistent with an autism 
spectrum disorder phenotype (Aller et al., 2015). 
Large scale genome-wide pharmacogenetics studies have also reported an association 
between variants within GluK4 and response to antidepressant treatment. For instance, 
variants in the 3’ region of GluK4 identified in the Sequenced Treatment Alternatives 
to Relieve Depression (STAR*D) clinical trial were found to affect patients’ response 
to citalopram antidepressant treatment (Paddock et al., 2007). Subsequently, intronic 
variants within GluK4 have now been consistently reported as moderating both 
antidepressant and antipsychotic efficacy and tolerability (Drago et al., 2013).  
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The aim of this study was to compare cognitive performance in subjects carrying the 
protective 3’UTR GluK4 deletion with subjects homozygous for the insertion genotype, 
in members of the TwinsUK population cohort in order to assess whether the GluK4 
deletion genotype could be a marker of protection against developing disease-
associated cognitive deficits. Clinical data is available which allows the TwinsUK 
Cohort to be divided into subsets of individuals with various psychiatric and 
neurological disorders. Information is also available on current and past use of 
antidepressant, antipsychotic and antiepileptic medication. We hypothesized that 
carriers of the deletion allele would perform better than individuals homozygous for the 
insertion in tasks assessing specific aspects of cognition. We analysed cognitive test 
data, controlling for medication use, in members of the TwinsUK cohort with known 
GluK4 indel genotype status.  
 
Materials and methods 
Sample population 
The TwinsUK cohort is a repository of approximately 12,000 monozygotic and 
dizygotic British twins who have been serially assessed for health traits. Procedures 
used for sample and data collection have been described previously (Spector et al., 
2006). TwinsUK was approved by the Guy’s and St Thomas’ Ethics Committee. 
Phenotypic data for TwinsUK was requested and approved through the TwinsUK 
Resource Executive Committee (TREC) based at the Department of Twins Research 
and Genetic Epidemiology at Kings College London. The study was carried out in 
accordance with The Code of Ethics of the World Medical Association (Declaration of 
Helsinki) for experiments involving humans. Baseline phenotypic measurements were 
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taken between 1992 and 2004 followed by multiple surveying sweeps and clinical 
visits. Recruitment to the TwinsUK cohort was voluntary. Individuals included in this 
analysis are all female. The ages ranged from 17 to79 years with a mean of 49 years. 
Genotype Data 
The aim of the UK10K project is to genome-wide sequence and deeply phenotype 
cohorts to assess the role of genetic variants in health and disease (Walter et al., 2015). 
Genotype data for the TwinsUK cohort was accessed from the European Genome-
phenome Archive (EGA; accession numbers EGAD00001000194 & 
EGAD00001000741) following a data access agreement with the UK10K project. 
Permission to link the genotype and phenotype data was also granted by TREC. 
Processing of next generation whole exome sequencing was performed by the 
Wellcome Trust Sanger Institute (Cambridge) using GATK and mapped to build 
GRCh37/hg19. Sequencing Variant Calling Files (VCFs) were downloaded from the 
EGA website and the VCFtools program was used to splice out the GluK4 co-ordinates 
[chr11:120,511,746 bp – 120,988,904 bp] from each VCF file. Selected BAM files were 
downloaded and processed using SAMtools and visualised using IGV to confirm 
sequencing quality in the region of the indel. The minor allele frequency of the deletion 
in the general population (MAF) is ~0.21 and individuals identified as carrying either 
one (heterozygous) or two (homozygous) copies of the deletion were grouped as 
deletion carriers.  We obtained access to genetic data for 1870 individuals. Of these, 
there were no processed sequencing data for 184 individuals and forty-four individuals 
were excluded because of low sequencing read depth and poor sequencing quality. A 
total of 1642 individuals remained of which 1158 were homozygotes for the insertion 
genotype (HOM INS) and 484 deletion allele carriers (DEL).  
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Cognitive Tests 
Cognitive performance was assessed by the National Adult Reading Test (NART), 
which is widely accepted as an estimate of premorbid intelligence levels, and four 
Cambridge Neuropsychological Test Automated Battery (CANTAB) tests;  the spatial 
working memory task (SWM), paired associates learning (PAL), reaction time (RTI), 
and the pattern recognition memory task (PRM). SWM assesses the retention and 
manipulation of visuospatial information, and the outcome measure used was the 
number of errors.  PAL assesses visual memory and new learning, and the outcome 
measure used was the number of errors. RTI provides an assessment of motor and 
mental response speeds.  PRM is a test of visual pattern recognition memory in a two-
choice forced discrimination paradigm, with the outcome measure being the speed of 
subjects’ responses. Principal Component Analysis using each cognitive test outcome 
measure was performed to identify domains of cognition which may have differed 
between individual groups.  
Diagnostic groups and medication status 
Information about clinical diagnosis and medication history was provided by TREC, 
Department of Twins Research and Genetic Epidemiology at King’s College London.  
The initial TwinsUK survey grouped participants into three diagnostic groupings; 
“learning disabilities”, “mental health problems” and “other neurological disorders”. 
For the current analysis we retained the three main diagnostic groupings but excluded 
cases with learning disability or epilepsy from the “mental health problems” group 
because both learning disability and epilepsy are associated with specific patterns of 
cognitive deficits. The “learning disabilities” group included individuals both with and 
without co-morbid “mental health problems”. Secondly all individuals with a diagnosis 
9 
 
of epilepsy, some of whom were co-morbid with learning disabilities or mental health 
problems, were included in a single “epilepsy” group.  
This gave a total of five diagnostic groups:  no clinical phenotype (N=1071), learning 
disability (N=23); mental health problems (N=259); epilepsy (N=231); other 
neurological diseases (N=58). The “mental health problem” group included individuals 
with a diagnosis of clinical depression (163), bipolar disorder (2), anxiety and stress-
related disorders (31), eating disorders (15) and 48 individuals with mental health 
problems about which no clear definition was available. The “other neurological 
disorders” group included neuropathies, stroke, multiple sclerosis, migraine and 
Parkinson’s disease. Analysis using these specific diagnostic groups was conducted 
only when the number of individuals exceeded 10 in each group. 
Current and past medication status was obtained:  individuals who receive no regular 
medication (N =365), antidepressants (N =150), antipsychotics (N =45). Individuals 
without diagnostic information who had taken antipsychotic, antidepressant or anti-
epileptic medication in the past, were included within the mental health alone and 
epilepsy subgroupings.   
Statistical analysis 
Pearson’s correlation coefficient (r) was calculated to examine correlations between 
individual cognitive tests. Cognitive data was tested for a normal distribution using the 
Kolmogorov-Smirnov test and the Shapiro-Wilk test. If data did not show a normal 
distribution, the logarithm of the values was used for further analysis. No outliers were 
identified or removed. PCA using each cognitive test outcome measure was performed 
to identify latent factors representing domains of cognition which may have differed 
between individual groups. The output variables from PCA were measured with the 
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Kaiser-Meyer-Olkin (KMO) measure of sampling adequacy and the Barlett’s test of 
sphericity.  
Multivariate linear regression analyses were used to compare cognitive performance 
between the genotype groups. The derived diagnosis and medication variables were 
included as covariates. Z-scores of cognitive performance were generated and used to 
compare genotype, diagnosis and medication group relationships. Pearson’s chi-
squared tests were performed to examine differences between diagnosis and medication 
status. As we hypothesized that carriers of the GluK4 deletion allele will perform better 
in the cognitive tests, statistical analysis was one-tailed and statistical significance was 
considered at p < 0.05. 
 
Results 
Comparison of cognitive test outcome measures 
Table 1 presents the Pearson’s correlation coefficients between each cognitive test 
outcome measure. Errors in paired associates learning (PAL) showed a significant 
positive correlation with spatial working memory task (SWM) errors (r > 0.39, p < 
0.001), and with latency in the pattern recognition memory (PRM) (r > 0.26, p < 0.001) 
and reaction time (RTI) (r > 0.26, p < 0.001) tests. SWM errors also showed a 
significant positive association with RTI latency (r > 0.18, p < 0.01). As would be 
expected for two tests which assess mental response speed, PRM and RTI latency were 
also correlated (r > 0.24, p < 0.0001). There was no significant correlation between 
performance on the NART test and any of the CANTAB performance, supporting the 
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distinction between general intelligence measured by NART and specific facets of 
cognition evaluated by the CANTAB tasks.  
Insert Table 1 here. 
Principal Component Analysis (PCA) identified two derived cognitive factors. The first 
factor included PAL errors (component loading 0.59), PRM latency (component 
loading 0.74), RTI latency (component loading 0.74), RTI latency (component loading 
0.67), and NART score (component loading 0.32) as presented in Table 2. As 
performance in these measures is associated with visuospatial mnemonic indices and 
speed of response, we refer to this factor as ‘visuo-spatial ability and mental speed’. 
The second factor comprised of performance in PAL errors (component loading 0.53), 
and SWM errors (component loading 0.73), and NART score (component loading -
0.675), shown in Table 2. As this grouping includes general intelligence, response times 
and errors in visual discriminatory we refer to this factor as ‘general intelligence and 
visual discrimination’. 
Insert Table 2 here. 
Cognitive performance and GluK4 genotype 
Table 3 presents the mean, standard error (SEM), F statistic, p values and partial-eta2 
(hp2) effect size for cognitive performance for the two genotype groups (HOM INS 
homozygous insertion versus DEL deletion carriers), unadjusted and adjusted and for 
co-variance with diagnosis. Cognitive performance profiles for each genotype are also 
presented as Z-scores in Figure 1. As indicated in Figure 1A, DEL carriers displayed 
more variance in cognitive performance compared to HOM INS individuals. Only one 
task, the SWM CANTAB task, showed a trend towards significance when comparing 
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performance scores in the two genotype groups (HOM INS 1.57 ± 0.019; DEL 1.51 ± 
0.035) (Figure 1B ). This trend became significant when diagnosis was included as a 
co-variate (F = 3.056, p = 0.041, hp2 = 0.017) with the DEL carriers making fewer SWM 
errors than the HOM INS individuals. No difference between the two genotype groups 
was observed for performance in either of the derived PCA factors. 
Insert Figure 1 here.   Insert Table 3 here. 
Cognitive performance and diagnosis of neurological and mental disorders 
Of the 1642 TwinsUK cohort members assessed, 571 individuals were reported to have 
a diagnosis of a mental health or neurological disorder. As these diagnoses were varied 
and often co-morbid, individuals with a diagnosis were categorized into the following 
groups: mental health problems alone (MH) N = 259; learning disability including 
learning disability with mental health problems (LD/LD & MH) N = 23; epilepsy 
including epilepsy co-morbid with other conditions (EP) N = 231; and, other 
neurological diseases (Other) N = 58. The numbers per diagnostic group for the GluK4 
indel genotype groups are presented in Table 4. No difference in diagnosis was 
observed with genotype status (χ2 = 0.602, df = 4, p = 0.963).  
Within these respective diagnostic groupings, cognitive performance in two measures 
was found to differ between the genotypes. DEL carriers performed better than HOM 
INS individuals within the ‘mental health problems alone’ group (MH) in the derived 
‘visuospatial memory and mental speed’ derived factor (N = 259, F = 3.176, df = 1, p 
= 0.043, hp2 = 0.102). In addition, a significant statistical difference in NART scores 
within the ‘other neurological disorders group’ was evident (N = 58 F = 8.006, df = 1, 
p = 0.009, hp2 = 0.235), where again GluK4 DEL carriers showed better performance 
in this general IQ test than HOM INS individuals (Figure 1C). Although the numbers 
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within each group were relatively small, the effect sizes for these genotype differences 
in performance were relatively large. 
Insert Table 4 here. 
Cognitive performance and medication 
Cohort members who reported a history of taking antipsychotic, antidepressant or 
antiepileptic medication were assessed in conjunction with diagnostic history (Figure 
1B). Table 5 presents the number of individuals on each type of medication in total and 
split by genotype group. 195 individuals were reported to have taken medication and 
had a diagnosis of disease, corresponding to ~12% of the total number of individuals 
with diagnosis and medication status both available (Figure 1B). However, 74 
individuals had no reported history of medication (they did not receive daily medication 
for over one month) but had a diagnosis. This corresponded to a ~4.5% of the total 
number of individuals with a diagnosis and medication status both available (Figure 
1B).  
To investigate the relationship between medication and the GluK4 indel genotype, 
individuals were categorized as taking antidepressants, other medication 
(antipsychotics, benzodiazepines, barbiturates) or no medication.  Table 5 presents the 
number of individuals on each type of medication in total and for the separate genotype 
groups. The number of individuals who had taken antidepressant medication or other 
medication showed no difference between the genotype groups (χ2 = 0.653, df = 2, p = 
0.722).  Differences in cognitive performance were assessed between GluK4 HOM INS 
individuals and DEL carriers who took no medication and individuals who received 
either antidepressants, antipsychotics or other medication. The effect of taking 
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medication was found not to influence cognitive performance between the two 
genotype groups (p > 0.259 for all cognitive tests).  
Insert Table 5 here.  
 
Discussion 
Impairments in working memory, attention and executive function are amongst the 
main cognitive deficits found in schizophrenia, bipolar disorder depression, and anxiety 
(Ferreri et al., 2011; Millan et al., 2012). We tested the hypothesis that a deletion variant 
within GluK4 reported to confer protection against developing bipolar disorder would 
show an association with better cognitive performance in a number of domain-specific 
cognitive tasks in unaffected individuals, and in individuals with “mental health 
problems”, learning disabilities and individuals with “other brain diseases”. 
The cognitive profile of 1642 individuals from the TwinsUK study indicated a 
significant difference in spatial working memory performance between the DEL 
carriers and HOM INS genotype groups in the “mental health problems “ group who 
almost entirely came under the umbrella diagnosis of “mood disorders”, mainly 
depression and anxiety. Consistent with previous research, we discovered that DEL 
carriers made fewer errors in spatial working memory. We also found that DEL carriers 
who had a mental health illness showed better performance in ‘visuo-spatial ability and 
mental speed’ than HOM INS individuals.  
 Furthermore, DEL carriers within the ‘the other neurological disorders’ group showed 
better performance in the National Adult Reading Test, NART, than HOM INS 
individuals. As NART is a test which is commonly used to assess premorbid 
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intelligence, i.e.  more general cognitive ability, we might expect more general deficits 
which are not domain specific to be evident in a group who has neurological diseases 
which include Parkinson’s disease, stroke, neuropathy, multiple sclerosis and migraine 
(McGurn et al., 2004). However, our findings show that although there was overall no 
difference in NART between this diagnostic grouping and the others assessed, there 
was a highly significant genotype effect for NART scores, with DEL carriers 
performing better than HOM INS individuals. This would suggest that the GluK4 indel 
allele could be relevant to a broader disease phenotype than has previously been 
investigated and therefore has the potential to be a biological marker of function 
relevant to neurological disease prognosis. Future studies should aim to explore further 
the neuroprotective role of GluK4 deletion allele through both preclinical and 
neurological disease cohort studies. 
The current study also provides evidence that an allele which modulates GluK4 protein 
abundance in both the frontal cortex and hippocampal regions such as the CA3 and 
dentate gyrus granule cells, is also involved in modulating memory function associated 
with hippocampal neuronal circuitry. We found that healthy and disease affected 
deletion carriers performed better in SWM, a test which involves hippocampal 
processing, i.e. the contextual component of spatial memory.  These findings are 
consistent with the report that non-diseased GluK4 deletion carriers show increased 
hippocampal activity during a face-processing task (Whalley et al., 2009).  
However, in contrast to our predictions, a difference in performance on the 
hippocampal-dependent CANTAB PAL test was not clearly shown. Nevertheless, DEL 
carriers who were identified as having a mental health problem performed better in the 
PCA-derived cognitive factor which included fewer errors in PAL, faster reaction time 
in visual pattern recognition (PRM) and visual object processing (RTI), indices which 
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are all dependent on the ‘what’, ‘where’ and ‘when’ components of contextual 
hippocampal processing. We speculate that the underlying mechanism may involve 
decrease in GluK4 receptor function associated with the insertion allele, adding to an 
already maladaptive, allostatic dysregulation of key neurotransmitter systems in 
individuals with mental health disorders, which results in disrupted processing within 
specific pathways and regions of the brain and impairment in distinct affiliated 
cognitive domains.  Further neuropsychological testing combined with brain imaging 
of healthy and diseased cohorts may help to elucidate which additional brain structures 
are of importance to this GluK4 indel genotype effect.   
The use of pharmacogenetics to predict patients’ response to antidepressant treatments 
has become an increasingly important goal. Previous studies have identified variants 
within GluK4 which showed significant association with antidepressant and 
antipsychotic treatment efficacy. Although no difference between the genotypes was 
observed in the number of individuals on medication and different medication types, 
the number of individuals taking medication was low and we could not investigate 
treatment response. Therefore, it is possible that the GluK4 indel could also contribute 
to a similar pharmacogenetics effect. Further studies will be needed to examine whether 
the GluK4 indel could be a valid human biomarker helpful in identifying drugs with a 
significant risk of reducing depression during clinical use.  
Findings from recent GWAS array and next generation sequencing exome studies of 
affected populations and multigenerational pedigrees, indicate shared genetic variation 
contributing to risk for schizophrenia, bipolar disorder as well as other brain diseases 
(Cross-Disorder Group of the Psychiatric Genomics, 2013; Knight et al., 2009; Singh 
et al., 2017). One such large GWAS study recently reported an association between 
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high frequency variants of small effect spanning the major histocompatibility complex 
(MHC) and risk for schizophrenia and bipolar disorder (International Schizophrenia et 
al., 2009). Subsequent studies examining this locus identified multiple risk haplotypes 
composed of common alleles within the complement component 4 (C4) gene (Sekar et 
al., 2016). Although the C4 gene is involved in the immune system classical complement 
cascade, the C4 protein is highly expressed in post synaptic compartments in neurons. 
Of interest, members of a second complement cascade protein family (C1ql2 and C1ql3) 
are also located at postsynaptic sites and are known to bind directly to the amino-terminal 
domains of kainite GluK2 and GluK4 KAR receptor subunits and hence regulate 
recruitment and function of ionotropic glutamate receptors at synapses (Matsuda, 
2017). 
 
Unlike many other genes found associated with mental illness, GluK4 research has 
provided consistent and replicated findings linking risk for mood disorders with 
molecular and proteomic changes, neurotransmission deficits and differential brain 
regional activity.  The current novel findings suggest that the deletion allele also 
contributes to improved non domain-specific general cognitive ability in individuals 
with neurological diseases as well as better performance in domain-specific 
hippocampal dependent cognition in individuals with mood disorders.  These studies 
show the potential clinical utility of the GluK4 indel in personalized medicine strategies 
and provide new insight into the relationship between genetic variation, neurobiology 
and disease.  
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Figure 1. Cognitive performance as grouped by genotype status and specific 
diagnostic groups and relationship between self-reported medication and 
diagnosis. Panel A The cognitive profile of GRIK4 DEL carriers and HOM INS 
homozygotes when diagnosis is added as a co-variate factor. The mean of Z-scores of 
each cognitive test and SEM is displayed for each genotype group.  Panel B Venn 
diagram showing the percentage of overlap between medication group (red – “Med”), 
no medication group (blue – “No med”) and diagnosis (yellow – “Diag”). Panel C 
Cognitive performance for both genotypes in the SWM task with and without diagnosis 
as a co-variate, and, performance in NART and PCA Factor 1 (visuospatial memory 
and mental speed) within the other neurological disorders group and mental health 
problems group respectively. Cognitive performance is shown as logged test scores and 
p-values less than 0.05 indicate a significant difference in performance. Other neuro 
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denotes ‘other neurological disorders’ group and MH denotes ‘mental health problems’ 
group. 
logPAL: logged paired associates learning, logSWM: logged spatial working memory, 
logPRM: logged pattern recognition memory, logRTI: logged reaction time, logNART: 
logged national adult reading test, SWM: spatial working memory, NART: national adult 
reading test, PCA F1: PCA Factor 1, Med: medication, No med: no medication, Diag: 
diagnosis.  
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Table 1: Correlation coefficients between cognitive performance in individual tests 
and derived cognitive factors.  Positive Pearson’s r values indicate a positive correlation 
between test performances whilst negative values indicate a negative correlation. NART 
performance does not show a correlation with the attention and memory tests, whereas 
there is a positive association between the SWM, PAL and RTI tests.  r values are 
significant at either the p < 0.05 (*) , p < 0.01 (**) or p < 0.001 (***) level. SWM: spatial 
working memory, NART: national adult reading test, PRM: pattern recognition memory, 
RTI: reaction time, PAL: paired associates learning. 
 
 
 
 
 
 
 
logPAL 
 
logSWM 
 
logPRM 
 
logRTI 
 
logNART 
 
logPAL 
 
- 
 
0.399*** 
 
0.264*** 
 
0.262*** 
 
-0.077 
 
logSWM 
  
- 
 
0.030 
 
0.185** 
 
-0.120 
 
logPRM 
   
- 
 
0.243*** 
 
0.075 
logRTI    
 
- 
 
0.011 
logNART     
 
- 
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Table 2: PCA component loadings for the two derived factors; visuo-spatial ability 
and mental speed, and general intelligence and visual discrimination. “PCA F1” 
denotes a ‘visuo-spatial ability and mental speed’ factor and “PCA F2” denotes a ‘general 
intelligence and visual discrimination’ factor. SWM: spatial working memory, NART: 
national adult reading test, PRM: pattern recognition memory, RTI: reaction time, PAL: 
paired associates learning. 
 
 
 
 
 
 
 
 
 
Component 
 
PCA F1 
Visuo-spatial ability and 
mental speed 
PCA F2 
General intelligence and 
visual discrimination 
PAL errors 0.593 0.525 
SWM errors  0.731 
PRM latency 0.742  
RTI latency 0.670  
NART score 0.316 -0.675 
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Cognitive test 
 
HOM INS 
Mean 
(SEM) 
 
DEL 
Mean 
(SEM) 
 
 
hp2 
 
 
 
 
P-Value 
 
 
 
hp2 
With 
diagnosis 
 
P-value 
With 
diagnosis 
 
logSWM 
 
1.56 
(0.019) 
 
1.51 
(0.035) 
 
0.013 
 
0.065 
 
0.017 
 
0.041* 
 
logNART 
 
1.55 
(0.016) 
 
1.55 
(0.023) 
 
0.000 
 
0.445 
 
0.000 
 
0.449 
 
 
logPRM 
 
3.33 
(0.010) 
 
3.33 
(0.014) 
 
0.000 
 
0.390 
 
0.000 
 
0.388 
 
 
logRTI 
 
2.57 
(0.006) 
 
2.58 
(0.008) 
 
0.003 
 
0.228 
 
0.001 
 
0.369 
 
 
logPAL 
 
1.43 
(0.018) 
 
1.41 
(0.023) 
 
0.003 
 
0.247 
 
0.006 
 
0.138 
 
Visuo-spatial ability & 
processing speed 
 
0.02 
(0.097) 
 
0.01 
(0.102) 
 
0.000 
 
0.462 
 
0.002 
 
0.302 
 
General intelligence 
and memory speed 
 
0.09 
(0.095) 
 
-0.16 
(0.121) 
 
0.012 
 
0.068 
 
0.014 
 
0.055 
 
 
Table 3: Mean cognitive performance in TwinsUK cohort members as grouped by 
genotype status. Mean, standard error (SEM), effect size (partial-eta squared, (hp2) and 
p values are presented. Statistical values are also presented when diagnosis is added as 
a covariate. HOM INS: homozygotes for the insertion genotype, DEL: deletion allele 
carriers, SWM: spatial working memory, NART: national adult reading test, PRM: 
pattern recognition memory, RTI: reaction time, PAL: paired associates learning. 
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Diagnosis 
 
 Data* INS/INS DEL 
No diagnosis 
  
1071 
 
751 
(70.1%) 
320 
(29.9%) 
Mental health  problems 
 259 
 
183 
(70.7% ) 
76 
(29.3%) 
LD and LD with mental health 
 23 
 
17 
(73.9%) 
6 
(26.1%) 
Epilepsy and comorbid epilepsy 
 231 
 
164 
(71.0% ) 
67 
(29.0%) 
Other neurological disorders 
 
58 
 
43 
(74.1% ) 
15 
(25.9%) 
 
Table 4:  Clinical diagnosis status of individuals in the genotype groups, HOM INS 
and DEL carriers. Numerical values indicate the actual numbers of individuals for 
each diagnosis group and in each genotype group. Percentages indicate the number of 
individuals per genotype group for each diagnostic group. The asterisk (*) symbolizes 
the number of genotyped individuals within each diagnosis group. HOM INS: 
homozygotes for the insertion genotype, DEL: deletion allele carriers. 
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Table 5:  Medication status of individuals in the HOM INS and DEL carrier 
genotype groups. The percentages and numbers of each medication and no “daily” 
medication group are shown in the “All” column. Numerical values indicate the actual 
numbers of individuals for each medication group and per genotype group.  “BDZ” and 
“Brb” denote treatment with benzodiazepines or barbiturates respectively. HOM INS: 
homozygotes for the insertion genotype, DEL: deletion allele carriers. 
 
 
 
 
 
 
Medication All  INS/INS          DEL 
No “daily” medication 
365 
 
257 
(70.4%) 
108 
(29.6%) 
Antidepressants 
150 
 
104 
(69.3%) 
46 
(30.7%) 
Others (Antipsychotics, BDZ, Brb) 
45 
 
34 
(75.6%) 
11 
(24.4%) 
